Back to Search Start Over

Subtilisin-like Serine Protease 1 (SUB1) as an Emerging Antimalarial Drug Target: Current Achievements in Inhibitor Discovery.

Authors :
Lidumniece E
Withers-Martinez C
Hackett F
Blackman MJ
Jirgensons A
Source :
Journal of medicinal chemistry [J Med Chem] 2022 Oct 13; Vol. 65 (19), pp. 12535-12545. Date of Electronic Publication: 2022 Sep 22.
Publication Year :
2022

Abstract

Widespread resistance to many antimalarial therapies currently in use stresses the need for the discovery of new classes of drugs with new modes of action. The subtilisin-like serine protease SUB1 controls egress of malaria parasites (merozoites) from the parasite-infected red blood cell. As such, SUB1 is considered a prospective target for drugs designed to interrupt the asexual blood stage life cycle of the malaria parasite. Inhibitors of SUB1 have potential as wide-spectrum antimalarial drugs, as a single orthologue of SUB1 is found in the genomes of all known Plasmodium species. This mini-perspective provides a short overview of the function and structure of SUB1 and summarizes all of the published SUB1 inhibitors. The inhibitors are classified by the methods of their discovery, including both rational design and screening.

Details

Language :
English
ISSN :
1520-4804
Volume :
65
Issue :
19
Database :
MEDLINE
Journal :
Journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
36137276
Full Text :
https://doi.org/10.1021/acs.jmedchem.2c01093